Medical Xpress

MAY 8, 2023

GLP1 receptor agonists—a class of diabetes medications—are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.

Drugs 98

Drugs Medicine Cardiology 98

FDA Law Blog

NOVEMBER 10, 2024

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. who intend to evaluate a drug, biologic, medical device, or food for medical purposes that targets a rare disease in a clinical trial. Relative to other areas of medicine (e.g.,

Production 69

Production Clinical Development Development Regulation 69

Scienmag

NOVEMBER 19, 2020

Department of Molecular Pharmacology, Shinshu University School of Medicine, Japan Researchers have identified a new druggable target for heart failure in neonates and infants, a condition for which there has been no specific treatment. Credit: Mitsuhiko Yamada MD, PhD.,

Medicine 97

Medicine Drugs Development Research 97

Medical Xpress

DECEMBER 7, 2022

Mann Department of Biomedical Engineering have developed a "heart attack on a chip," a device that could one day serve as a testbed to develop new heart drugs and even personalized medicines. Researchers at the University of Southern California Alfred E.

Engineer 104

Engineer Medicine Development Drugs 104

Scienmag

NOVEMBER 13, 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Medicine 61

Medical Xpress

MAY 10, 2023

In an effort to determine the cause behind a rare condition that causes heart failure in children, University of Maryland School of Medicine (UMSOM) researchers have identified new gene mutations responsible for the disorder in an infant patient.

Research 98

Research Gene Medicine Drugs 98

FDA Law Blog

FEBRUARY 21, 2022

Unger has joined the firm as a Principal Drug Regulatory Expert. Dr. Unger is a cardiologist and former Director of the Office of Drug Evaluation-I in FDA’s Office of New Drugs in the Center for Drug Evaluation and Research (“CDER”). He completed his cardiology training at The Johns Hopkins Hospital in 1987.

Drugs 40

Drugs Cardiology FDA Approval Doctors 40

Scienmag

JULY 26, 2021

NEW YORK, NY (July 26, 2021)–Two types of drugs that are recommended as a first treatment for patients with high blood pressure were found equally effective in improving cardiovascular outcomes, but the more popular type causes slightly more side effects, finds a multinational observational study led by researchers at Columbia University Vagelos (..)

Drugs 75

Drugs Research Cardiology Medicine 75

Scienmag

SEPTEMBER 24, 2020

Sophia Antipolis, 25 September 2020: Short-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients with COVID-19 who are risk assessed prior to receiving the drug. That’s the finding of research published today in EP Europace, a journal of the European Society of Cardiology (ESC).1

Cardiology 46

Cardiology Drugs Research Medicine 46

XTalks

JANUARY 3, 2025

Ionis Pharmaceuticals recently announced that its drug, Tryngolza (olezarsen), has been approved as an adjunct to diet for the reduction of triglyceride levels in FCS patients, who have long faced a condition with no existing pharmacological solutions. In the Balance study, patients who received the drug showed a 42.5

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

pharmaphorum

DECEMBER 21, 2020

Novartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster because a manufacturing facility has yet to be inspected. The European Commission has already approved the drug under the brand name Leqvio earlier this month following backing from the CHMP regulatory committee.

Drugs 52

Drugs RNA Manufacturing Licensing 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Seattle Gummy Company’s breakthrough gummy drug program, which delivers Active Pharmaceutical Ingredients (APIs) in its innovative gummy matrix, recently won its first Investigational New Drug Application (IND) approval from FDA on the company’s allergy gummy medication, designated as IND 140312.

Drugs 40

Drugs Allergies Cardiology Medicine 40

Rethinking Clinical Trials

JUNE 7, 2023

The drugs were administered open label and all patients were given a low dose of aspirin. The study drug was mailed directly to participants, and at the end of the trial participants were instructed to destroy the drug. The trial took place at 64 sites, and randomized 863 patients.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Cardiology 100

pharmaphorum

JULY 6, 2021

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug. Novartis added inclisiran to its pipeline after buying The Medicines Company, which had licensed the drug from Alnylam, for $9.7

RNA 105

RNA Manufacturing Sales Drugs 105

Scienmag

OCTOBER 21, 2020

Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Drugs 73

Drugs Research Clinical Trials Clinical Trials 73

Scienmag

OCTOBER 28, 2020

Drugs prescribed to high-risk stroke patients are costing the NHS hundreds of millions each year – but they are so effective, the service is actually saving money.

Drugs 63

Drugs Cardiology Medicine 63

Scienmag

SEPTEMBER 15, 2020

15, 2020 — Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to “Drug- Induced Arrhythmias,” a new scientific statement from the American Heart Association, published today in the Association’s flagship journal Circulation.

Medicine 41

Medicine Drugs Cardiology 41

XTalks

JULY 19, 2021

It screens for inherited genetic conditions across various medical areas, including oncology and cardiology, hearing and vision loss, infertility, endocrinology, gastroenterology, mental and behavioral health, drug responses, sleep, nutrition, exercise and diet.

Genetics 98

Genetics Genome Genomics Gene 98

The Pharma Data

JUNE 28, 2021

The approval is based on the results of the pivotal Phase III VICTORIA trial, published in The New England Journal of Medicine (NEJM) in March 2020. Food and Drug Administration (FDA) in January 2021 and was recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) in the EU in May 2021.

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

MARCH 22, 2022

senior vice president, head of cardiovascular development and global drug development at Bristol Myers Squibb. “We Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. About Mavacamten. Source link: [link].

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. About Grzegorz Kania, MD Grzegorz Kania, MD specializes in cardiology as well as internal and family medicine. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 15, 2020

Researchers tracking a Reddit forum on CBD found many folks discussing use of cannabidiol to treat conditions for which there are proven, safe and effective medicines and therapies. doesn’t think there is cause for alarm just because people are reaching beyond conventional medicine to treat their health problems. THURSDAY, Oct.

Production 52

Production Medicine Doctors Doctor 52

Pharma Marketing Network

FEBRUARY 27, 2025

Scientific Articles & Whitepapers HCPs rely on credible, research-backed content to stay informed about new treatments, drug efficacy, and emerging medical trends. Pharma brands can develop: Whitepapers on clinical trials showcasing drug effectiveness. Behind-the-scenes research lab videos showcasing drug development.

Branding 52

Branding Marketing Compliance Pharma Companies 52

Scienmag

APRIL 19, 2021

A new publication in JAMA Internal Medicine focuses on the minimal pros and the concerning cons of combining a daily aspirin with a drug from the newer class of anticoagulants that include apixaban, dabigatran, edoxaban and rivaroxaban. More blood thinners aren’t automatically better, another study confirms.

Medicine 41

Medicine Drugs Cardiology 41

The Pharma Data

FEBRUARY 21, 2022

We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. Tackling this challenge with advanced technologies and products, radiology is a key enabler to transform healthcare, expanding personalized medicine and improving outcomes for patients.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

OCTOBER 14, 2020

Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

Scienmag

MARCH 24, 2021

Platform developed by Tempus, Geisinger CHICAGO, March 24, 2020 — Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform, developed in collaboration with Geisinger.

Medicine 40

Medicine Development Drugs Bioinformatics 40

pharmaphorum

JUNE 1, 2021

Patients will also receive a dose of tacrolimus, an immune-suppressing drug, to guard against any immune reaction to the transplanted cells. The hope is that the spheroids will help to replenish damaged cardiomyocytes in the heart, restoring some of its ability to pump blood around the body.

Trials 138

Trials Development Licensing Licensing 138

Scienmag

NOVEMBER 15, 2020

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites (..)

Antibody 40

Antibody Medicine Drugs Clinical Trials 40

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

Medicine 52

Medicine RNA Production Marketing 52

Scienmag

NOVEMBER 16, 2020

ET, Monday, November 16, 2020, Cleveland: Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of […].

Trials 41

Trials FDA Approval Clinical Trials Clinical Trials 41

Scienmag

SEPTEMBER 29, 2020

Twenty percent of children treated with drugs called anthracyclines […].

Development 77

Development Drugs Research Cardiology 77

Scienmag

AUGUST 30, 2020

Sophia Antipolis, France – 31 Aug 2020: There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to the most extensive study conducted on the topic.

Drugs 66

Drugs Research Cardiology Medicine 66

Trialfacts

APRIL 2, 2024

Upon entering the treatment phase, there will be a 16-week ramp-up period during which the amount of study drug is gradually increased to aid the body in acclimating to the treatment. Throughout this period, participants will be required to take the study medicine for approximately 2 years.

Research 52

Research Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 2, 2020

Food and Drug Administration (FDA) approval of Bronchitol (mannitol) inhalation powder. About Bronchitol® (mannitol) inhalation powder Bronchitol is a prescription medicine that is used along with other therapies to improve lung function in people 18 years of age and older with cystic fibrosis (CF). About Chiesi USA Chiesi USA, Inc.,

FDA Approval 52

FDA Approval Bacteria Medicine Cardiology 52

The Pharma Data

NOVEMBER 19, 2020

But after giving the patients an unmarked eight-month supply of statins and dummy pills (four bottles of each), the investigators found that 90% of the symptoms reported when taking the real drug endured, even when patients were taking a dummy (placebo) pill. 15 in the New England Journal of Medicine.

Cardiology 52

Cardiology Drugs Research Containment 52

Scienmag

MAY 16, 2021

NEW YORK, NY (May 16, 2021)–Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian. (..)

Drugs 51

Drugs Research Cardiology Medicine 51